Does Humana Cover Testosterone Enanthate?

Humana Commercial Plan Coverage for Testosterone Enanthate

Humana commercial plans generally include testosterone enanthate on their formulary for the treatment of male hypogonadism. The drug most often sits on Tier 2 as a preferred generic, which means copays range from $10 to $45 depending on the specific plan design. Some high-deductible health plans (HDHPs) require members to meet the annual deductible before copay pricing applies.

Coverage is not automatic. Humana requires prescribers to submit a prior authorization (PA) request documenting the clinical need for testosterone replacement therapy (TRT). The Endocrine Society's 2018 clinical practice guideline recommends TRT only in men with symptomatic testosterone deficiency confirmed by at least two morning serum total testosterone measurements below 300 ng/dL [1]. Humana's PA criteria closely mirror this recommendation.

The prescriber must also document the presence of specific symptoms: reduced libido, erectile dysfunction, fatigue, decreased muscle mass, or depressed mood. A 2016 analysis from the Testosterone Trials (TTrials), published in the New England Journal of Medicine and enrolling 790 men aged 65 and older with testosterone levels below 275 ng/dL, found that testosterone treatment for one year improved sexual function, physical activity, and mood compared to placebo [2]. This trial remains a key piece of evidence supporting TRT in older men with confirmed low testosterone.

Humana may also request documentation that reversible causes of hypogonadism have been evaluated. Clinicians should note any workup for pituitary disorders, medication-induced suppression (particularly opioids or glucocorticoids), and obstructive sleep apnea before initiating therapy.

Prior Authorization Criteria: What Humana Requires

The prior authorization process for testosterone enanthate on Humana is moderate in complexity. Expect a decision within 5 to 10 business days for standard requests, or 72 hours for urgent requests.

Humana's PA form typically requires the following documentation:

• Two morning serum total testosterone levels below 300 ng/dL, drawn between 7:00 AM and 10:00 AM on separate days. The American Urological Association (AUA) uses a threshold of 300 ng/dL as a reasonable cutoff to identify men who may benefit from TRT [3].
• Clinical symptoms consistent with testosterone deficiency.
• LH and FSH levels to distinguish primary from secondary hypogonadism.
• Documentation that topical formulations were considered or attempted. Some plans enforce step therapy, requiring trial of a topical testosterone gel before approving an injectable formulation.
• Confirmation that the patient does not have contraindications, including breast or prostate cancer, untreated polycythemia (hematocrit above 54%), or uncontrolled heart failure.

The FDA label for testosterone enanthate specifies its approved use in conditions associated with a deficiency or absence of endogenous testosterone, including primary hypogonadism and hypogonadotropic hypogonadism [4]. Off-label uses, such as testosterone therapy for age-related decline without clinical hypogonadism, face higher denial rates.

A practical approach to PA success: submit the two lab draws, symptom documentation, and a brief clinical note explaining why injectable testosterone enanthate is preferred over topical formulations (for example, inconsistent absorption with gels, skin irritation, or concern about transference to household contacts). Including the clinical rationale in the initial submission reduces back-and-forth with the plan and shortens approval time.

Humana Medicare Advantage: Stricter Rules Apply

Medicare Advantage (MA) plans administered by Humana follow CMS guidelines, which are more restrictive than commercial plan criteria. Coverage for testosterone enanthate under Part D (pharmacy benefit) requires a confirmed diagnosis of hypogonadism with ICD-10 code E29.1 and supporting laboratory evidence.

CMS does not cover testosterone therapy prescribed solely for weight management, age-related fatigue, or general wellness. A 2020 study published in JAMA Internal Medicine found that 25.4% of men initiating testosterone therapy did not have a testosterone level measured before treatment, raising concerns about inappropriate prescribing [5]. Humana MA plans have tightened authorization requirements partly in response to these prescribing patterns.

MA plan members should expect the following differences from commercial coverage:

• Higher denial rates for initial requests. The PA process may require additional documentation, including a specialist note from an endocrinologist or urologist.
• Quantity limits. Many MA plans limit dispensing to a 200 mg/mL, 5 mL vial every 30 days.
• Step therapy enforcement. Some Humana MA plans require a documented trial of topical testosterone (such as AndroGel 1.62% or generic testosterone gel) before approving the injectable form.

The typical Humana MA copay for a Tier 2 generic testosterone enanthate sits between $15 and $47 per month during the initial coverage phase. After the coverage gap (donut hole), out-of-pocket costs increase until the catastrophic coverage threshold is reached.

Step Therapy Requirements on Humana Plans

Step therapy is a cost-control mechanism where the plan requires you to try a less expensive or preferred medication before approving an alternative. On some Humana plans, testosterone enanthate (injectable) is classified as a step-two drug, meaning topical testosterone must be tried and documented as ineffective, poorly tolerated, or clinically inappropriate before the injectable is approved.

This is not universal across all Humana plans. Many commercial plans allow direct access to injectable testosterone enanthate without step therapy, particularly when the prescriber documents a clinical reason for choosing the injectable route. Valid reasons include:

• Patient preference for biweekly dosing over daily topical application
• Risk of skin-to-skin transference to female partners or children
• History of skin reactions to topical formulations
• Superior pharmacokinetic profile for specific clinical scenarios

A 2004 pharmacokinetic study demonstrated that intramuscular testosterone enanthate 200 mg every two weeks produces peak serum testosterone of approximately 1,200 ng/dL at 3 to 5 days post-injection, with a nadir near 400 ng/dL at day 14 [6]. Some clinicians now prescribe weekly or split-dose protocols (100 mg weekly or 50 mg every 3.5 days) to reduce the peak-trough fluctuation, though Humana's quantity limits may complicate these dosing schedules.

If your Humana plan imposes step therapy, your prescriber can request a step therapy exception. This requires a letter explaining why the preferred drug is not appropriate for you, supported by clinical documentation.

How to Appeal a Humana Denial of Testosterone Enanthate

Denials happen. When Humana denies coverage for testosterone enanthate, the denial letter will include the specific reason (missing labs, insufficient documentation, off-label use, or step therapy not completed) and instructions for appeal.

Commercial plan appeals follow a two-level internal process:

1. First-level internal appeal. You or your prescriber submit additional documentation within 180 days of the denial. Humana must respond within 30 calendar days for standard appeals or 72 hours for expedited appeals involving urgent medical need.
2. Second-level internal appeal. If the first appeal is denied, request a second internal review. This review is conducted by a physician not involved in the original decision.
3. External review. After exhausting internal appeals, you can request an independent external review through your state's insurance department.

Medicare Advantage appeals follow a different path dictated by CMS:

1. Coverage determination redetermination. File within 60 days of the denial. Humana must respond within 7 days (standard) or 72 hours (expedited).
2. Independent Review Entity (IRE). If Humana upholds the denial, the case automatically moves to an IRE. For Medicare Part D, the IRE is currently MAXIMUS Federal Services.
3. Administrative Law Judge (ALJ) hearing. Available if the amount in controversy meets the CMS threshold (currently $180 for 2026).

Tips for a successful appeal:

• Include a letter of medical necessity from the prescribing physician that references the Endocrine Society guidelines and the specific lab values
• Attach copies of the two morning testosterone levels and the LH/FSH results
• If step therapy was the basis for denial, document the dates and outcomes of the topical testosterone trial
• Reference the T-Trials data showing clinical benefit in men with confirmed testosterone deficiency [2]

Cost Comparison: Insurance vs. Cash Pay

Understanding the cost field helps you decide whether to use Humana benefits or pay out of pocket.

| Scenario | Estimated Monthly Cost | |---|---| | Humana commercial (Tier 2 copay) | $10 to $45 | | Humana Medicare Advantage (initial phase) | $15 to $47 | | Manufacturer list price | ~$120 | | Cash pay (GoodRx or similar) | ~$40 to $70 | | Telehealth TRT clinic (including labs) | $100 to $250 |

Generic testosterone enanthate 200 mg/mL (5 mL vial) is widely available. The cash price at major pharmacies has dropped significantly since multiple generic manufacturers entered the market. For patients facing a high-deductible plan or a PA denial, cash pay at $40 to $70 per month may be less expensive than fighting the insurance process, at least temporarily while an appeal is pending.

Manufacturer savings cards typically apply only to brand-name testosterone formulations (such as Delatestryl) and do not stack with Medicare, Medicaid, or other government-funded insurance. If you have Humana commercial insurance, a manufacturer savings card for the brand product could reduce your copay, but generic testosterone enanthate is almost always cheaper than the brand with any available coupon.

Monitoring Requirements That Affect Ongoing Coverage

Humana may require periodic documentation that monitoring labs are being performed before reauthorizing testosterone enanthate on renewal. The Endocrine Society recommends the following monitoring schedule for men on TRT [1]:

• Total testosterone level at 3 to 6 months after initiation, then annually. Target trough level: 400 to 700 ng/dL (measured just before the next injection).
• Hematocrit at baseline, 3 to 6 months, then annually. Testosterone stimulates erythropoiesis, and hematocrit above 54% requires dose reduction or phlebotomy. A large Veterans Affairs study (N = 5,695) found that 3.4% of men on injectable testosterone developed polycythemia requiring intervention [7].
• PSA at baseline and at 3 to 12 months. A rise greater than 1.4 ng/mL within 12 months or an absolute value above 4.0 ng/mL warrants urologic evaluation.
• Lipid panel and metabolic markers annually, especially in men with cardiovascular risk factors. The TRAVERSE trial (N = 5,204), published in the New England Journal of Medicine in 2023, found that testosterone replacement in hypogonadal men with cardiovascular risk did not increase the incidence of major adverse cardiac events compared to placebo over a mean follow-up of 33 months [8].

Failure to document appropriate monitoring can lead to PA renewal denials. Prescribers should maintain a structured follow-up schedule and ensure lab results are in the chart before the reauthorization window opens.

State-Level Variations in Humana Testosterone Coverage

Humana operates across all 50 states, but formulary details, copay tiers, and PA requirements vary by state and by specific plan. Members in states with strong parity laws for hormone therapy (such as California and New York) may encounter fewer barriers. Members in states where Humana has fewer negotiated pharmacy contracts may see higher copays.

To find your exact coverage details:

1. Log into your Humana member portal at humana.com
2. Use the formulary search tool and enter "testosterone enanthate"
3. Check the PA and step therapy indicators next to the drug listing
4. Call the number on your member ID card for plan-specific questions

Your prescriber's office can also call Humana's provider line to verify benefits and initiate a PA before writing the prescription, reducing delays at the pharmacy counter.